Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting. The ...

Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

(CAPR) on ...

Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 9:2. Implied volatility suggests the market is ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

The biotechnology company posted adjusted earnings per share of -$0.16 for Q4, beating analyst estimates by $0.01. Revenue came in at $11.13 million, significantly above the consensus forecast of ...

Q4 2024 Management View CEO Linda Marban highlighted the acceptance by the FDA of Capricor's Biologics License Application (BLA) for deramiocel, targeting treatment of Duchenne muscular dystrophy (DMD ...

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research ...

Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference-- SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), on Monday, announced positive data from its ongoing HOPE-2 open-label extension trial, demonstrating the long-term efficacy of Deramiocel for the ...